Alphatec Holdings, Inc. ATEC
We take great care to ensure that the data presented and summarized in this overview for Alphatec Holdings, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ATEC
View all-
Black Rock Inc. New York, NY8.29MShares$84.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.97MShares$60.8 Million0.0% of portfolio
-
American Century Companies Inc Kansas City, MO4.99MShares$50.8 Million0.03% of portfolio
-
Braidwell LP Stamford, CT4.26MShares$43.4 Million2.19% of portfolio
-
Bnp Paribas Asset Management Holding S.A.4.01MShares$40.9 Million0.09% of portfolio
-
Royal Bank Of Canada Toronto, A63.19MShares$32.5 Million0.01% of portfolio
-
Bank Of America Corp Charlotte, NC2.96MShares$30.2 Million0.0% of portfolio
-
State Street Corp Boston, MA2.92MShares$29.7 Million0.0% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL2.58MShares$26.3 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA2.39MShares$24.3 Million0.0% of portfolio
Latest Institutional Activity in ATEC
Top Purchases
Top Sells
About ATEC
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; Sigma transforaminal lumbar interbody fusion pedicle-based access system that provides direct visualization of anatomical landmarks; Sigma PTP Access and Patient Positioning System; squadron lateral retractor designed to maximize patient outcomes; Invictus Spinal Fixation System, a thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep System that provides minimally invasive pedicle screw placement. It also provides Invictus Modular Fixation Systems designed to increase adaptability with the power of screw modularity; OsseoScrew system to restore the integrity of the spinal column; Arsenal spinal fixation system, a comprehensive thoracolumbar fixation platform to fix a range of degenerative to deformity pathologies and surgical procedures; Aspida Anterior Lumbar Plating System, a fixation system for anterior lumbar interbody fusion; AMP Anti-Migration Plate; OCT Spinal Fixation System; trestle luxe anterior cervical plate system; and Insignia Anterior Cervical Plate System. In addition, the company offers IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Interbody Implants; and biologics consisting of Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix, and Amnioshield Amniotic Tissue Barrier, as well as EOS imaging products. It sells its products through a network of independent distributors and direct sales representatives in the United States. The company was founded in 1990 and is headquartered in Carlsbad, California.
Insider Transactions at ATEC
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 10
2025
|
Scott Lish CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
27,994
-3.31%
|
$251,946
$9.72 P/Share
|
Mar 10
2025
|
John Todd Koning CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
165,121
-25.47%
|
$1,486,089
$9.72 P/Share
|
Mar 07
2025
|
Patrick Miles CEO |
SELL
Open market or private sale
|
Direct |
12,691
-0.22%
|
$126,910
$10.64 P/Share
|
Mar 06
2025
|
David Sponsel EVP, SALES |
SELL
Open market or private sale
|
Direct |
33,732
-4.8%
|
$337,320
$10.83 P/Share
|
Mar 06
2025
|
Patrick Miles CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
70,097
-1.18%
|
$771,067
$11.44 P/Share
|
Mar 06
2025
|
Tyson Eliot Marshall GENERAL COUNSEL & CORP. SEC. |
SELL
Payment of exercise price or tax liability
|
Direct |
27,805
-5.81%
|
$305,855
$11.44 P/Share
|
Mar 03
2025
|
Karen K Mcginnis |
SELL
Open market or private sale
|
Direct |
38,320
-39.97%
|
$459,840
$12.26 P/Share
|
Feb 27
2025
|
Scott Lish CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
23,183
-2.67%
|
$278,196
$12.03 P/Share
|
Feb 26
2025
|
Patrick Miles CEO |
SELL
Open market or private sale
|
Direct |
32,393
-0.54%
|
$323,930
$10.89 P/Share
|
Feb 25
2025
|
David Sponsel EVP, SALES |
SELL
Open market or private sale
|
Direct |
19,419
-2.69%
|
$194,190
$10.41 P/Share
|
Feb 24
2025
|
David Sponsel EVP, SALES |
SELL
Open market or private sale
|
Direct |
12,946
-1.76%
|
$129,460
$10.73 P/Share
|
Feb 24
2025
|
Patrick Miles CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
92,988
-1.53%
|
$929,880
$10.76 P/Share
|
Feb 06
2025
|
Scott Lish CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
27,453
-3.07%
|
$301,983
$11.49 P/Share
|
Feb 05
2025
|
Patrick Miles CEO |
SELL
Open market or private sale
|
Direct |
43,459
-0.71%
|
$478,049
$11.95 P/Share
|
Feb 03
2025
|
David Sponsel EVP, SALES |
SELL
Open market or private sale
|
Direct |
36,256
-4.7%
|
$398,816
$11.42 P/Share
|
Jan 30
2025
|
Patrick Miles CEO |
SELL
Open market or private sale
|
Direct |
43,313
-0.7%
|
$519,756
$12.03 P/Share
|
Jan 29
2025
|
Patrick Miles CEO |
SELL
Open market or private sale
|
Direct |
50,000
-0.81%
|
$600,000
$12.03 P/Share
|
Jan 29
2025
|
Patrick Miles CEO |
BUY
Grant, award, or other acquisition
|
Direct |
700,829
+3.7%
|
-
|
Jan 29
2025
|
Scott Lish CHIEF OPERATING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
314,269
+11.14%
|
-
|
Jan 29
2025
|
Craig E Hunsaker EVP, PEOPLE & CULTURE |
BUY
Grant, award, or other acquisition
|
Direct |
352,061
+6.98%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 2.43M shares |
---|---|
Exercise of conversion of derivative security | 182K shares |
Open market or private purchase | 190K shares |
Bona fide gift | 15.1K shares |
---|---|
Payment of exercise price or tax liability | 214K shares |
Open market or private sale | 881K shares |